Explication simple
Lyfgenia treats the same disease as Casgevy and was approved by the FDA on the same day, but it works differently. Instead of editing a switch in the patient's DNA, it uses a modified virus to add a new, specially designed haemoglobin gene into blood stem cells. The added gene makes a haemoglobin that resists sickling. Same disease, same day, two genuinely different technologies.
Aller plus loin
Lovotibeglogene autotemcel is an autologous haematopoietic stem cell product transduced with a lentiviral vector encoding a modified beta-globin gene, βA-T87Q, which inhibits HbS polymerisation. Approved by the FDA in December 2023 for sickle cell disease with a history of vaso-occlusive events in patients 12 and over. It carries a boxed warning for haematological malignancy following reported cases in the development programme.
Why both exist, and why the difference matters
This pair is the best available illustration of gene addition versus gene editing. Casgevy edits the patient's own DNA at a regulatory switch. Lyfgenia inserts an engineered gene at a semi-random location using a lentiviral vector. Both are autologous, both require the same conditioning chemotherapy, both are given once.
The risks differ. Lentiviral integration carries insertional-mutagenesis risk, and Lyfgenia carries a boxed warning for haematological malignancy after cases were reported in its development programme. That is a difference in mechanism producing a difference in labelled risk — exactly the kind of distinction that collapses when both are described simply as 'gene therapy for sickle cell'.
Sources
- U.S. Food and Drug Administration · 2023
FDA approves first gene therapies to treat patients with sickle cell disease ↗